Main Menu

Tumor-specific mutated proteins can create neoepitopes, mutation-derived antigens that distinguish tumor cells from healthy cells, which are attractive targets for adoptive cell therapies. However, the process of precisely identifying the neoepitopes to target is complex and challenging. One method to identify such neoepitopes is Mass Spectrometry (MS) when used in conjunction with elution of peptides bound to a specific Human Leukocyte Antigen (HLA) allele.

There is growing awareness that a wide variety of synthetic and natural compounds that may be present in water sources, such as streams, wells, and ground water, may lead to adverse health effects, including increased cancer risk. Even low concentrations of these compounds are of concern, as they may have biological effects at concentrations of parts per billion or less.

Human leukocyte antigen (HLA) LOH (LOH) is a known resistance mechanism by which cancers evade T cell receptor-(TCR-)based immunotherapies. This class of therapies includes immune checkpoint inhibition (ICI, e.g., Pembrolizumab), engineered TCR (T cell receptor)-T cell adoptive transfer, tumor infiltrating lymphocytes (TIL), T-cell engagers, and other modalities. Dozens of therapies in this category were developed with many in clinical trials. The resistance mechanism noted here, HLA LOH, causes these therapies to fail.

Biological homeostasis is a state of steady internal, physical, and chemical conditions maintained by a living organism observed at the cellular level.  Biological homeostasis can vary in order to alter the cellular physical and chemical conditions.

Measuring and mapping nervous tissue microstructure noninvasively is a long sought-after goal in neuroscience. Several neuropathologies – such as cancer and stroke – are associated with changes in tissue microstructure. Changes in material properties, such as stiffness, represent a sensitive measure of

Measuring and mapping nervous tissue microstructure noninvasively is a long sought-after goal in neuroscience. Clinically, several neuropathologies such as cancer and stroke, are associated with changes in tissue microstructure. Diffusion tensor imaging (DTI), which models diffusion anisotropy, is an ideal imaging modality to elucidate these changes. However, DTI provides a mean diffusion tensor averaged over the entire MRI voxel. This has limitations when applied to heterogeneous neural tissue.

DNA or RNA-based diagnostic tests for infectious diseases are critical in modern medicine. The current gold standard for COVID-19 detection is testing SARS-CoV-2 viral RNA by quantitative reverse transcription Polymerase Chain Reaction (RT-qPCR). This method involves patient sample collection with a nasopharyngeal swab, storage of the swab in a universal transport medium during transport to testing site, RNA extraction, and analysis of the extracted RNA sample.

Traumatic brain injury (TBI) represents a major medical, social and economic concern worldwide due to significant mortality – especially among younger populations – and long-term disabilities. Various pathological brain lesions (e.g., intracerebral bleedings, necrotic-ischemic lesions, tissue avulsion) are produced by impacting mechanical forces. Among these, diffuse axonal injury (DAI) is one of the most significant brain lesions typically associated with trauma. However, DAI is not necessarily linked with TBI exposure. Therefore, the term “traumatic axonal injury (TAI)” is commonly used.

The use of tumor transcriptomics for precision oncology has made significant advances, mainly by identifying cancer driver genes or actionable mutations for treatment with targeted therapies.  However, this strategy misses out on broader genetic interactions that could reveal additional biologically testable biomarkers for therapy response prediction and inform the selection of more effective drugs for targeted treatment.

The development of precision medicine approaches for DLBCL (Diffuse Large B Cell Lymphoma) is complicated by its genetic, phenotypic and clinical heterogeneity. Current classification methods do not fully explain the observed differences in clinical outcomes to current chemotherapy and targeted therapy. Therefore, better analytical methods to classify and predict DLBCL patients’ treatment response are needed.